À retenir
Across 23 placebo-controlled trials with 1213 participants, oral potassium lowered systolic blood pressure by 4.25 mm Hg (95% CI -5.96 to -2.53) and diastolic by 2.53 mm Hg versus placebo in primary hypertension. The trials differed noticeably on the diastolic result (I2 = 65%), and the abstract's safety claim comes with no adverse-event numbers.
Study design
Méta-analyse d’essais
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Eating more potassium has been linked to lower blood pressure, but it was unclear whether potassium taken as a supplement works as a treatment for high blood pressure. The authors set out to measure how much oral potassium supplements change systolic and diastolic pressure compared with placebo in people with primary (essential) hypertension.
Population et méthode
Systematic review and meta-analysis of randomized, placebo-controlled trials of potassium supplementation lasting at least 4 weeks in people with primary hypertension. The authors searched Medline, Web of Science, Scopus and the Cochrane Central Register of Controlled Trials until October 2016, screened reference lists and set no language limits; 9059 articles led to 23 included trials with 1213 participants. They took systolic and diastolic blood pressure at final follow-up and pooled the mean difference (MD) in a random-effects model, checking heterogeneity with Cochran's test and I2 and publication bias with Begg's and Egger's tests. The abstract does not give the potassium doses.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Versus placebo, potassium supplements lowered systolic blood pressure by a mean 4.25 mm Hg (95% CI -5.96 to -2.53; I2 = 41%), a modest but statistically significant drop.
- 2Diastolic pressure fell by a mean 2.53 mm Hg (95% CI -4.05 to -1.02; I2 = 65%). The higher I2 means the trials disagreed more on this outcome than on systolic pressure.
- 3In a change-score analysis using 8 of the 23 trials (change from baseline, compared between groups), the systolic difference was -8.89 mm Hg (95% CI -13.67 to -4.11) and the diastolic difference -6.42 mm Hg (95% CI -10.99 to -1.84). These are larger than the main analysis, which compared final values.
- 4The authors conclude that potassium is safe with no important adverse effects and may be an add-on blood pressure treatment; the abstract gives no adverse-event counts or blood potassium data to check that.
Limites et incertitude
- 1The change-score estimates come from only 8 of the 23 trials, and the abstract does not report the potassium doses, the individual trial sizes or how long trials ran beyond the 4-week minimum.
- 2Heterogeneity was moderate to substantial (I2 = 41% for systolic, 65% for diastolic), and the abstract does not report the results of the publication-bias tests.
- 3Blood pressure is a surrogate outcome; the abstract reports no data on heart attacks, strokes or adverse events, so the 'safe' conclusion rests on information not shown. This reading is based on the abstract only.
Mise en perspective
In trials lasting at least 4 weeks, potassium supplements gave a modest average drop in blood pressure, a few mm Hg, which should not be treated as a stand-in for prescribed treatment. Potassium is handled differently in people with kidney problems or those taking certain blood pressure medicines, so whether a supplement is suitable, and at what dose, is a decision to make with your clinician. This abstract says nothing about getting potassium from food.
Vos données
A home blood pressure cuff is how you would see any change: measure at the same times each day, seated and rested, and compare weekly averages before and after, because day-to-day swings in single readings can swamp a difference of a few mm Hg. If you and your clinician agree to try a supplement, log what you take and your potassium-rich foods next to the readings and bring that record to follow-up; your clinician may also check potassium with blood tests.
Comprendre ce type de preuve
Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Importance
Increased dietary potassium intake is thought to be associated with low blood pressure (BP). Whether potassium supplementation may be used as an antihypertensive agent is a question that should be answered.
Objective
To assess the effect of oral potassium supplementation on blood pressure in patients with primary hypertension.
Search methods
We searched Medline, Web of Science, Scopus, Cochrane Central Register of Controlled Trials until October 2016. We also screened reference lists of articles and previous reviews. We applied no language restrictions.
Selection criteria
We included randomized placebo-controlled clinical trials addressing the effect of potassium supplementation on primary hypertension for a minimum of 4 weeks.
Data collection and analysis
We extracted data on systolic and diastolic BP (SBP and DBP) at the final follow-up. We explored the heterogeneity across studies using Cochran's test and I2 statistic and assessed the probability of publication bias using Begg's and Egger's tests. We reported the mean difference (MD) of SBP and DBP in a random-effects model.
Results
We found a total of 9059 articles and included 23 trials with 1213 participants. Compared to placebo, potassium supplementation resulted in modest but significant reductions in both SBP (MD -4.25 mmHg; 95% CI: -5.96 to -2.53; I2 = 41%) and DBP (MD -2.53 mmHg; 95% CI: -4.05 to -1.02; I2 = 65%). According to the change-score analysis, based on 8 out of 23 trials, compared to baseline, the mean changes in SBP (MD -8.89 mmHg; 95% CI: -13.67 to -4.11) and DBP (MD -6.42 mmHg; 95% CI: -10.99 to -1.84) was significantly higher in the intervention group than the control group.
Conclusions
Our findings indicated that potassium supplementation is a safe medication with no important adverse effects that has a modest but significant impact BP and may be recommended as an adjuvant antihypertensive agent for patients with essential hypertension.
Sources et attribution
Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials.
Poorolajal J, Zeraati F, Soltanian AR, Sheikh V, Hooshmand E, Maleki A.
PloS one · 2017-04-18
DOI: 10.1371/journal.pone.0174967 ↗PubMed · 28419159 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
A salt substitute lowered stroke, major cardiovascular events and death in rural China
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
The New England Journal of Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine

